Resilience awarded DoD contract for mAb countermeasure to botulinum neurotoxins and has a multi-year agreement to produce mNRA for Moderna's Covid-19 vaccine.
Analysis of VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus).
Programs are mRNA vaccine candidates against herpes simplex virus, varicella-zoster virus to reduce the rate of shingles and new checkpoint cancer vaccine.
Includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain.
Growth attributable to revenues from terminated UK COVID-19 vaccine supply agreement for non-refundable payments received for duration of the contract.
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.
Penn’s innovation in process science combines with CBM manufacturing capability for large-scale gene therapy manufacturing capacity, testing and analytics.
Aims to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets in the field of neurodegenerative diseases.